The University of Glasgow uses cookies for analytics. Find out more about our Privacy policy.
Necessary cookies enable core functionality. The website cannot function properly without these cookies, and can only be disabled by changing your browser preferences.
Analytical cookies help us improve our website. We use Google Analytics. All data is anonymised.
Clarity helps us to understand our users’ behaviour by visually representing their clicks, taps and scrolling. All data is anonymised.
email:
Judith.Dixon@glasgow.ac.uk
pronouns:
She/her/hers
Wolfson Wohl Cancer Research Centre, University of Glasgow, Garscube Estate, Switchback Road, Glasgow, G61 1QH
Moss, J. G. et al. (2021) Central venous access devices for the delivery of systemic anticancer therapy (CAVA): a randomised controlled trial. Lancet, 398(10298), pp. 403-415. (doi: 10.1016/S0140-6736(21)00766-2) (PMID:34297997)
Wu, O. et al. (2021) Venous access devices for the delivery of long-term chemotherapy: the CAVA three-arm RCT. Health Technology Assessment, 25(47), (doi: 10.3310/hta25470)
Lakis, V. et al. (2021) DNA methylation patterns identify subgroups of pancreatic neuroendocrine tumors with clinical association. Communications Biology, 4, 155. (doi: 10.1038/s42003-020-01469-0) (PMID:33536587) (PMCID:PMC7859232)
Vennin, C. et al. (2019) CAF hierarchy driven by pancreatic cancer cell p53-status creates a pro-metastatic and chemoresistant environment via perlecan. Nature Communications, 10, 3637. (doi: 10.1038/s41467-019-10968-6) (PMID:31406163) (PMCID:PMC6691013)
Ryan, C., Hesselgreaves, H., Wu, O. , Moss, J. G., Paul, J. , Dixon-Hughes, J. and Germeni, E. (2019) Patient acceptability of three different central venous access devices for the delivery of systemic anticancer therapy: a qualitative study. BMJ Open, 9(7), e026077. (doi: 10.1136/bmjopen-2018-026077) (PMID:31292176) (PMCID:PMC6624052)
Ryan, C., Hesselgreaves, H., Wu, O. , Paul, J. , Dixon-Hughes, J. and Moss, J. G. (2018) Protocol for a systematic review and thematic synthesis of patient experiences of central venous access devices in anti-cancer treatment. Systematic Reviews, 7, 61. (doi: 10.1186/s13643-018-0721-x) (PMID:29669583) (PMCID:PMC5907379)
Jones, R. J. et al. (2017) Randomized phase II study investigating pazopanib versus weekly paclitaxel in relapsed or progressive urothelial cancer. Journal of Clinical Oncology, 35(16), pp. 1770-1777. (doi: 10.1200/JCO.2016.70.7828) (PMID:28402747)
Salji, M., Jones, R. , Paul, J. , Birrell, F., Dixon-Hughes, J., Hutchison, C., Johansen, T.E.B., Greene, D., Parr, N. and Leung, H.Y. (2014) Feasibility study of a randomised controlled trial to compare (deferred) androgen deprivation therapy and cryotherapy in men with localised radiation-recurrent prostate cancer. British Journal of Cancer, 111(3), pp. 424-429. (doi: 10.1038/bjc.2014.316)
Moss, J. G. et al. (2021) Central venous access devices for the delivery of systemic anticancer therapy (CAVA): a randomised controlled trial. Lancet, 398(10298), pp. 403-415. (doi: 10.1016/S0140-6736(21)00766-2) (PMID:34297997)
Wu, O. et al. (2021) Venous access devices for the delivery of long-term chemotherapy: the CAVA three-arm RCT. Health Technology Assessment, 25(47), (doi: 10.3310/hta25470)
Lakis, V. et al. (2021) DNA methylation patterns identify subgroups of pancreatic neuroendocrine tumors with clinical association. Communications Biology, 4, 155. (doi: 10.1038/s42003-020-01469-0) (PMID:33536587) (PMCID:PMC7859232)
Vennin, C. et al. (2019) CAF hierarchy driven by pancreatic cancer cell p53-status creates a pro-metastatic and chemoresistant environment via perlecan. Nature Communications, 10, 3637. (doi: 10.1038/s41467-019-10968-6) (PMID:31406163) (PMCID:PMC6691013)
Ryan, C., Hesselgreaves, H., Wu, O. , Moss, J. G., Paul, J. , Dixon-Hughes, J. and Germeni, E. (2019) Patient acceptability of three different central venous access devices for the delivery of systemic anticancer therapy: a qualitative study. BMJ Open, 9(7), e026077. (doi: 10.1136/bmjopen-2018-026077) (PMID:31292176) (PMCID:PMC6624052)
Ryan, C., Hesselgreaves, H., Wu, O. , Paul, J. , Dixon-Hughes, J. and Moss, J. G. (2018) Protocol for a systematic review and thematic synthesis of patient experiences of central venous access devices in anti-cancer treatment. Systematic Reviews, 7, 61. (doi: 10.1186/s13643-018-0721-x) (PMID:29669583) (PMCID:PMC5907379)
Jones, R. J. et al. (2017) Randomized phase II study investigating pazopanib versus weekly paclitaxel in relapsed or progressive urothelial cancer. Journal of Clinical Oncology, 35(16), pp. 1770-1777. (doi: 10.1200/JCO.2016.70.7828) (PMID:28402747)
Salji, M., Jones, R. , Paul, J. , Birrell, F., Dixon-Hughes, J., Hutchison, C., Johansen, T.E.B., Greene, D., Parr, N. and Leung, H.Y. (2014) Feasibility study of a randomised controlled trial to compare (deferred) androgen deprivation therapy and cryotherapy in men with localised radiation-recurrent prostate cancer. British Journal of Cancer, 111(3), pp. 424-429. (doi: 10.1038/bjc.2014.316)